NeoGenomics Company Profile (NASDAQ:NEO)

NeoGenomics trades on the NASDAQ under the ticker symbol "NEO."

NeoGenomics, Inc. (NASDAQ:NEO) announced its earnings results on Tuesday, July, 25th. The company reported $0.04 earnings per share for the quarter, topping the Zacks' consensus estimate of $0.01 by $0.03. The company earned $66.09 million during the quarter, compared to the consensus estimate of $62.95 million. NeoGenomics had a negative net margin of 2.81% and a positive return on equity of 6.09%. The company's revenue was up 4.7% on a year-over-year basis. During the same period in the previous year, the firm posted $0.04 earnings per share. View NeoGenomics' Earnings History.

NeoGenomics is scheduled to release their next quarterly earnings announcement on Tuesday, October, 24th 2017. View Earnings Estimates for NeoGenomics.

NeoGenomics issued an update on its FY17 earnings guidance on Tuesday, July, 25th. The company provided earnings per share (EPS) guidance of $0.17-0.21 for the period, compared to the Thomson Reuters consensus estimate of $0.18. The company issued revenue guidance of $255-265 million, compared to the consensus revenue estimate of $258.23 million.

5 brokerages have issued twelve-month target prices for NeoGenomics' stock. Their predictions range from $9.00 to $11.00. On average, they anticipate NeoGenomics' stock price to reach $10.50 in the next twelve months. View Analyst Ratings for NeoGenomics.

Here are some recent quotes from research analysts about NeoGenomics stock:

• 1. According to Zacks Investment Research, "NeoGenomics, Inc. is a high-complexity CLIA-certified clinical laboratory that specializes in cancer genetics diagnostic testing, the fastest growing segment of the laboratory industry. The company's testing services include cytogenetics, fluorescence in-situ hybridization, flow cytometry, morphology studies, anatomic pathology and molecular genetic testing. Headquartered in Fort Myers, FL, NeoGenomics has labs in Nashville, TN, Irvine, CA and Fort Myers and services the needs of pathologists, oncologists, urologists, hospitals and other reference laboratories throughout the United States. " (7/29/2017)
• 2. Cantor Fitzgerald analysts commented, "We reiterate our Overweight rating and $11 price target following last week's meeting with management. The company highlighted the strategic benefits of its tech-only offering, the Clarient acquisition, positive secular trends that are driving cancer diagnostics, and NEO's strong management team. The biggest takeaway, in our view, was that the Clarient integration continues to progress, which should drive further cost synergies as well as revenue synergies. We estimate that there is a $10-16M low-hanging revenue opportunity from targeting 100 Clarient accounts. We believe that the company will be able to unlock 25-40% of these and, thus, we are modeling $4-6M of revenue synergies ($2-3M in EBITDA contribution), with significant potential upside." (3/22/2017)

Some companies that are related to NeoGenomics include Akcea Therapeutics (AKCA), MyoKardia (MYOK), HMS Holdings Corp (HMSY), Tenet Healthcare Corporation (THC), Emergent Biosolutions (EBS), Immunomedics (IMMU), Radius Health (RDUS), Healthways (TVTY), Repligen Corporation (RGEN), Innoviva (INVA), Pacira Pharmaceuticals (PCRX), Quidel Corporation (QDEL), Phibro Animal Health Corporation (PAHC), CONMED Corporation (CNMD), Foundation Medicine (FMI), MiMedx Group (MDXG), USANA Health Sciences (USNA) and Lexicon Pharmaceuticals (LXRX).

NeoGenomics' management team includes the folowing people:

• Douglas M. VanOort, Chairman of the Board, Chief Executive Officer
• George A. Cardoza, Chief Financial Officer
• Robert J. Shovlin, Chief Operating Officer
• Steven C. Jones, Executive Vice President - Finance, Chief Compliance Officer, Director
• Edwin F. Weidig III, CPA, Principal Accounting Officer, Vice President - Finance
• Steven A. Ross, Chief Information Officer
• Steven G. Brodie Ph.d., Vice President - Operations
• Jennifer Balliet, Vice President - Human Resources
• Sally Agersborg M.D. Ph.D., Director of Hematopathology and Medical Director
• Maher Albitar M.D., Chief Medical Officer, Director - Research and Development

NeoGenomics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include General Electric Co. (18.93%), Vanguard Group Inc. (3.44%), First Light Asset Management LLC (3.37%), Artisan Partners Limited Partnership (2.98%), Janus Henderson Group PLC (2.90%) and Russell Investments Group Ltd. (2.52%). Company insiders that own NeoGenomics stock include Alison L Hannah, Bruce K Crowther, George Cardoza, Jennifer Balliet, Lynn A Tetrault, Maher Albitar, Oort Douglas M Van, Robert J Shovlin, Steven A Ross, Steven C Jones and Steven G Brodie. View Institutional Ownership Trends for NeoGenomics.

NeoGenomics' stock was sold by a variety of institutional investors in the last quarter, including Perkins Capital Management Inc., Uniplan Investment Counsel Inc., Wells Fargo & Company MN, Icon Advisers Inc. Co., Artisan Partners Limited Partnership, Kopp Investment Advisors LLC, Emerald Advisers Inc. PA and Swiss National Bank. Company insiders that have sold NeoGenomics stock in the last year include Jennifer Balliet, Maher Albitar, Steven A Ross and Steven G Brodie. View Insider Buying and Selling for NeoGenomics.

NeoGenomics' stock was acquired by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Falcon Point Capital LLC, Russell Investments Group Ltd., Granite Investment Partners LLC, Northpointe Capital LLC, Royce & Associates LP, Strs Ohio and Rice Hall James & Associates LLC. Company insiders that have bought NeoGenomics stock in the last two years include Alison L Hannah, Bruce K Crowther, Lynn A Tetrault and Robert J Shovlin. View Insider Buying and Selling for NeoGenomics.

Shares of NeoGenomics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of NeoGenomics stock can currently be purchased for approximately $11.01.